NLRP3 and neoplasm: To determine whether the NLRP3 inflammasome activated by tumour antigen-specific CTLs contributes to their mediated antitumour immunity, we utilized a similar strategy (as depicted in Supplementary Fig. 5d) to analyse the ability of OT1-mediated antigen-specific killing of target tumour cells.